E-cigarette use or vaping: reporting suspected adverse reactions, including lung injury

Be vigilant for any suspected adverse reactions associated with use of e-cigarettes or vaping (including lung injury) and report them to the MHRA via the Yellow Card Scheme.

Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy

Recent epidemiological studies suggest exposure to ondansetron during the first trimester of pregnancy is associated with a small increased risk of the baby having a cleft lip and/or cleft palate.

Mecasermin (Increlex▼): risk of benign and malignant neoplasia

Cases of benign and malignant neoplasms have been observed among children and adolescents who received treatment with mecasermin.

Letters and drug alerts sent to healthcare professionals in December 2019

Letters were sent about Insuman insulin products, mecasermin, and valproate medicines.

Medical Device Alerts issued in December 2019

Alerts were issued about Arrow EZ-IO intraosseous vascular access needle sets, Medicina IV Luer Slip syringes, and Spectra Optia apheresis systems.

Posted on the UK MHRA website on 28 January 2020